A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeremy Shefner, MD, PhD
State University of New York - Upstate Medical University
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of British Columbia, Gordon and Leslie Diamond Health Care Centre - Tier 2 Site
Vancouver, British Columbia, Canada
- London Health Science Center - Tier 2 Site
London, Ontario, Canada
- University of Toronto, Sunnybrook Health Sciences Centre - Tier 2 Site
Toronto, Ontario, Canada
- Montreal Neurological Institute - Tier 2
Montreal, Quebec, Canada
- University of California Los Angeles - Tier 2 Site
Pacific Palisades, California, United States
- University of California - San Francisco - Tier 2 Site
San Francisco, California, United States
- University of Colorado Health Sciences Center - Tier 2 Site
Denver, Colorado, United States
- University of Miami - Tier 2 Site
Miami, Florida, United States
- Emory University - Tier 2 Site
Atlanta, Georgia, United States
- Northwestern University, Dept. of Neurology - Tier 2 Site
Chicago, Illinois, United States
- University of Kansas Medical Center - Tier 2 Site
Kansas City, Kansas, United States
- John Hopkins University - Tier 2 Site
Baltimore, Maryland, United States
- Massachusetts General Hospital - Tier 1 Site
Boston, Massachusetts, United States
- Baystate Medical Center - Tier 2 Site
Springfield, Massachusetts, United States
- Saint Louis University, Neuromuscular Div. - Tier 2 Site
St Louis, Missouri, United States
- Washington University - Tier 2 Site
St Louis, Missouri, United States
- Bryanlgh Medical Center - Tier 2 Site
Lincoln, Nebraska, United States
- Upstate Clinical Research, Llc - Tier 2 Site
Albany, New York, United States
- Columbia University Medical Center - Tier 2 Site
New York, New York, United States
- Mount Sinai School of Medicine - Tier 2 Site
New York, New York, United States
- Suny Downstate Medical Center - Tier 1 Site
Syracuse, New York, United States
- Duke University Medical Center - Tier 1 Site
Durham, North Carolina, United States
- Wake Forest University School of Medicine -Tier 2 Site
Winston-Salem, North Carolina, United States
- Cleveland Clinic Foundation -Tier 2 Site
Cleveland, Ohio, United States
- Providence Als Center - Tier 2 Site
Portland, Oregon, United States
- Pennsylvania State University School of Medicine - Tier 2 Site
Hershey, Pennsylvania, United States
- Drexel University College of Medicine - Tier 1 Site
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center - Tier 2 Site
Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center - Tier 2
Nashville, Tennessee, United States
- Texas Neurology, Pa - Tier 2 Site
Dallas, Texas, United States
- University of Texas Health Science Center - Tier 2 Site
San Antonio, Texas, United States
- University of Vermont, College of Medicine - Tier 2
Burlington, Vermont, United States
- University of Virginia - Tier 2 Sites
Charlottesville, Virginia, United States
- Virginia Mason Clinic - Tier 2 Site
Seattle, Washington, United States
- Medical College of Wisconsin - Tier 2 Site
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- —
- Primary completion
- —
- Completion
- —
- Last update posted
- 9 Feb 2012
- Registered enrollment
- 0
- Registry id
- NCT00561366
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.